Journal
CLINICAL INFECTIOUS DISEASES
Volume 75, Issue 1, Pages E403-E409Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciac014
Keywords
COVID-19; remdesivir; dexamethasone; survival; viral clearance
Categories
Ask authors/readers for more resources
Treatment with remdesevir plus dexamethasone in COVID-19 patients requiring supplemental O(2) therapy showed significant reduction in mortality, shorter hospital stay, and faster viral clearance.
Treatmentwith remdesevir plus dexamethasone in coronavirus disease 2019 (COVID-19) patients requiring supplemental O(2)therapy compared to dexamethasone alone showed higher 30-day survival, faster viral clearance, shorter length of hospital stay, and faster reduction of inflammatory markers and improvement of respiratory function. Background Remdesivir is an antiviral used to treat coronavirus disease 2019 (COVID-19), which improves some clinical outcomes. Dexamethasone has been shown to be effective in reducing mortality. It has been hypothesized that combination of these two drugs can improve mortality. We evaluated the effect of combination on mortality of COVID-19 patients requiring O-2 therapy. Methods A prospective quasi-experimental study, including two independent, sequential controlled cohorts, one received remdesivir-dexamethasone and the other dexamethasone alone, was designed. All COVID-19 patients requiring supplemental O-2 therapy were enrolled consecutively. The sample size to power mortality was a priori calculated. The primary endpoints were 30-day mortality and viral clearance differences. Secondary endpoints were differences in hospitalization times, improvement in respiratory failure (PO2/FiO(2)) and inflammatory indices (fibrinogen, CRP, neutrophil/lymphocyte ratio, D-Dimer). Kaplan-Meier curves and the log-rank test were used to evaluate significant differences in mortality between groups. Results In total, 151 COVID-19 patients were enrolled (remdesivir/dexamethasone group, 76, and dexamethasone alone, 75). No differences in demographic, clinical, and laboratory characteristics were observed between the 2 groups at baseline. Faster viral clearance occurred in the remdesivir/dexamethasone group compared to dexamethasone alone (median 6 vs 16 days; P < .001). The 30-day mortality in the remdesivir/dexamethasone group was 1.3%, whereas in dexamethasone alone was 16% (P < .005). In the remdesivir/dexamethasone group compared to dexamethasone alone there was a reduction in hospitalization days (P < .0001) and a faster improvement in both respiratory function and inflammatory markers. Conclusions Remdesivir/dexamethasone treatment is associated with significant reduction in mortality, length of hospitalization, and faster SARS-CoV-2 clearance, compared to dexamethasone alone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available